Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

NCT05409482 is registered in ClinicalTrials.gov with Meng Chao Hepatobiliary Hospital of Fujian Medical University as lead sponsor.

NCT NCT05409482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05409482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
Lead sponsor
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Phase
Observational
Overall status
Recruiting
Start date
August 20, 2022
Completion date
March 1, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma